Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
News
ASX Large Caps: Shares higher again as Megaport surges 13pc; mining and energy stocks retreat
News
Closing Bell: ASX falls flat after strong employment data muddies waters
Health & Biotech
Check Up: M&A activity in healthcare heats up as Aussie biotech Kinoxis attracts $181m from big pharma
News
Small Cap Recap and IPO Wrap: An ASX affair to remember
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but don’t throw the baby out with the bathwater
News
ASX Large Caps: Shares up 4pc this week, market welcomes ‘dovish’ Bullock as next RBA governor
News
In Case You Missed It: Tech, gold and a global pharma partnership
News
ASX Small Caps Lunch Wrap: Anyone else need anything from the servo this morning?
Health & Biotech
ASX Health Stocks: Market darling Neuren Pharma jumps 16pc on Acadia worldwide licence
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall in first week of FY23 as Mach 7 scores biggest deal in its history
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX Health Stocks: Ramsay Healthcare up 7pc as its looks to sell joint Asian Venture
Health & Biotech
ScoPo’s (actually Iain’s) Powerplays: ASX health stocks lower, Sigma wins back Chemist Warehouse deal from EBOS
Health & Biotech
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech